Citations

Clear

4847 citation(s) found for "Tu, Eric".

A Perfect Storm: Vibrio Necrotizing Fasciitis During Hurricane Season in Florida
Young, Maia C. , Zuberi, Eric , Seim, Lynsey A. , Hedges, Mary S. , James, Courtney L , Seim, Lynsey , Hedges, Mary S

Mayo Clinic

Annals of Internal Medicine: Clinical Cases | February 20, 2024 | Volume: 3 | Issue: 2 | Pages: No page available

10.7326/aimcc.2023.1204 Get It

Cardiac Magnetic Resonance Imaging in Heart Transplant Recipients with Biopsy-Negative Graft Dysfunction
Anand, Senthil, Alnsasra, Hilmi , LeMond, Lisa , Shrivastava, Sanskriti , Rosenbaum, Andrew , Kobrossi, Semaan, Mohananey, Akanksha, Murphy, Katie , Kushwaha, Sudhir S. , Steidley, D. Eric , Clavell, Alfredo L. , Young, Phillip M. , Pereira, Naveen L. , Lemond, Lisa M, Steidley, David E, Clavell, Alfredo, Young, Phillip, Asleh, Rabea , Smith, Byron H.

Mayo Clinic

ESC Heart Failure | February 20, 2024 | Volume: 11 | Issue: 3 | Pages: 1594-1601

10.1002/ehf2.14681 | PMID 38379022 Get It

Abstract Aims Graft dysfunction (GD) after heart transplantation (HTx) can develop without evidence of cell- or antibody-mediated rejection. Cardiac magnetic resonance imaging (CMR) has an evolving role in detecting rejection; however, its role in biopsy-negative GD has not been described. This study examines CMR findings, evaluates outcomes based on CMR results, and seeks to identify the possibility of rejection missed through endomyocardial biopsy by using CMR in HTx recipients with biopsy-negative GD. Methods and results HTx recipients with GD [defined as a decrease in left ventricular ejection fraction (LVEF) by >5% and LVEF < 50%] in the absence of rejection by biopsy or allograft vasculopathy and who underwent CMR were included in the study. The primary outcome was a composite of all-cause mortality, re-transplantation, or persistent LVEF < 50%. Overall, 34 HTx recipients developed biopsy-negative GD and underwent CMR. Left ventricular late gadolinium enhancement (LGE) on CMR was observed in 16 patients with two distinct patterns: diffuse epicardial (n = 13) and patchy (n = 3) patterns. Patients with LGE developed GD later after HTx [4 (1.4–6.8) vs. 0.8 (0.3–1.2) years, P < 0.001], were more often symptomatic (88% vs. 56%, P = 0.06), and had greater haemodynamic derangement (pulmonary capillary wedge pressure: 19 ± 7 vs. 13 ± 3 mmHg, P = 0.002) as compared with those without LGE. No significant difference was observed in the primary composite outcome between patients with LGE and those without LGE (50% vs. 38% of patients with events, P = 0.515). During a median follow-up of 3.8 years, mean LVEF improved similarly in the LGE-negative (37–55%) and LGE-positive groups (32–55%) (P = 0.16). Conclusions Biopsy-negative GD occurs with and without LGE when assessed by CMR, indicative of possible rejection/inflammation occurring only in a subset of patients. Irrespective of LGE, LVEF improvement occurs in most GD patients, suggesting that other neurohormonal or immunomodulatory mechanisms may also contribute to GD development.
The past, present, and future of the brain imaging data structure (BIDS)
Markiewicz, Christopher J. , Bansal, Shashank , Bénar, Christian , Bertazzoli, Giacomo , Bhogawar, Suyash , Blair, Ross , Brooks, Teon L , Calhoun, Vince D. , Castelli, Filippo Maria , D’Ambrosio, Sasha , Hollander, Gilles de , Vega, Alejandro de la , Delorme, Arnaud , Earl, Eric , Feingold, Franklin , Flandin, Guillaume, Galassi, Anthony , Gallitto, Giuseppe , Ganz, Melanie , Gholam, James , Ghosh, Satrajit , Guidali, Giacomo , Handwerker, Daniel A. , Hardcastle, Nell , Innis, Robert B. , Ioanas, Horea-Ioan , Jahn, Andrew , Karakuzu, Agâh , Kincses, Bálint , Lau, Jonathan C. , Li, Xiangrui , Meisler, Steven L. , Mikkelsen, Mark E. , Nichols, Thomas E. , Ort, Eduard , Park, Patrick J., Pawlik, Mateusz , Pestilli, Franco , Pollonini, Luca , Rizzo, Gaia , Robbins, Kay A. , Rockhill, Alexander P. , Rogers, Christine , Rokem, Ariel , Rorden, Chris , Routier, Alexandre , Saborit-Torres, Jose Manuel , Schirner, Michael , Smith, Robert E. , Sprenger, Julia , Szinte, Martin , Thomas, Adam G. , Torabian, Sajjad, Voytek, Bradley , Calhoun, Vince D. , Poldrack, Russell A. , Appelhoff, Stefan , Ashar, Yoni K. , Auer, Tibor , Baillet, Sylvain , Beltrachini, Leandro , Bortoletto, Marta , Boudreau, Mathieu , Clement, Patricia , Cohen, Alexander L. , Cohen-Adad, Julien , Iglesia-Vayá, María de la , Devinsky, Orrin , Draschkow, Dejan , Duff, Eugene Paul , DuPré, Elizabeth , Estéban, Oscar , Gau, Rémi , Ghosh, Satrajit S , Giacomel, Alessio , Gillman, Ashley , Gleeson, Padraig , Gramfort, Alexandre , Guay, Samuel , Halchenko, Yaroslav O. , Herholz, Peer , Hermes, Dora , Honey, Christopher John , Keator, David B. , Kiar, Gregory , Laird, Angela R. , Lazari, Alberto , Legarreta, Jon Haitz , Li, Adam , Love, Bradley C. , Lu, Hanzhang , Marcantoni, Eleonora , Maumet, Camille , Mazzamuto, Giacomo , Mutsaerts, Henk , Nikolaidis, Aki , Nilsonne, Gustav , Niso, Guiomar , Nørgaard, Martin Agge , Okell, Thomas W. , Oostenveld, Robert , Pernet, Cyril R , Petr, Jan , Phillips, Christophe L. M. , Poline, Jean‐Baptiste , Raamana, Pradeep Reddy , Ritter, Petra , Salo, Taylor , Spisák, Tamás , Swann, Nicole C. , Takerkart, Sylvain , Thirion, Bertrand , Varoquaux, Gaël , Welzel, Julius , Wilson, Martin , Yarkoni, Tal , Gorgolewski, Krzysztof J.

Mayo Clinic

Imaging Neuroscience | February 20, 2024 | Volume: 2 | Issue: No issue available | Pages: No page available

10.1162/imag_a_00103 | PMID 39308505 Get It

Abstract The Brain Imaging Data Structure (BIDS) is a community-driven standard for the organization of data and metadata from a growing range of neuroscience modalities. This paper is meant as a history of how the standard has developed and grown over time. We outline the principles behind the project, the mechanisms by which it has been extended, and some of the challenges being addressed as it evolves. We also discuss the lessons learned through the project, with the aim of enabling researchers in other domains to learn from the success of BIDS.
LungViT: Ensembling Cascade of Texture Sensitive Hierarchical Vision Transformers for Cross-Volume Chest CT Image-to-Image Translation
Chaudhary, Muhammad F. A. , Gerard, Sarah E. , Christensen, Gary E. , Cooper, Christopher B. , Schroeder, Joyce , Hoffman, Eric A. , Hoffman, Eric A , Reinhardt, Joseph M.

Mayo Clinic

IEEE Transactions on Medical Imaging | February 19, 2024 | Volume: 43 | Issue: 7 | Pages: 2448-2465

10.1109/tmi.2024.3367321 | PMID 38373126 Get It

Regional Practice Variation and Outcomes in the Standard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) Trial: A Post Hoc Secondary Analysis
Vaara, Suvi T. , Neto, Ary Serpa, Adhikari, Neill K. J. , Dreyfuss, Didier, Hoste, Eric A. J. , Joannidis, Michael , Pettilä, Ville , Wang, Ying , Investigators, on behalf of the STandard vs. Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI), Finfer, Simon , Orford, Neil , Bates, Samantha , Guitton, Christophe , Young, Paul J. , Rosenberg, Alex , Bihari, Shailesh , Finfer, Simon , Young, Paul J , Bellomo, Rinaldo , Gallagher, Martin , Gaudry, Stèphane , Kashani, Kianoush , Wald, Ron , Bagshaw, Sean M. , Ostermann, Marlies , Investigators, on behalf of the STandard vs. Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI)

Mayo Clinic

Critical Care Explorations | February 19, 2024 | Volume: 6 | Issue: 2 | Pages: e1053

10.1097/cce.0000000000001053 | PMID 38380940 Get It

OBJECTIVES: Among patients with severe acute kidney injury (AKI) admitted to the ICU in high-income countries, regional practice variations for fluid balance (FB) management, timing, and choice of renal replacement therapy (RRT) modality may be significant. DESIGN: Secondary post hoc analysis of the STandard vs. Accelerated initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial (ClinicalTrials.gov number NCT02568722). SETTING: One hundred-fifty-three ICUs in 13 countries. PATIENTS: Altogether 2693 critically ill patients with AKI, of whom 994 were North American, 1143 European, and 556 from Australia and New Zealand (ANZ). INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Total mean FB to a maximum of 14 days was +7199 mL in North America, +5641 mL in Europe, and +2211 mL in ANZ (p < 0.001). The median time to RRT initiation among patients allocated to the standard strategy was longest in Europe compared with North America and ANZ (p < 0.001; p < 0.001). Continuous RRT was the initial RRT modality in 60.8% of patients in North America and 56.8% of patients in Europe, compared with 96.4% of patients in ANZ (p < 0.001). After adjustment for predefined baseline characteristics, compared with North American and European patients, those in ANZ were more likely to survive to ICU (p < 0.001) and hospital discharge (p < 0.001) and to 90 days (for ANZ vs. Europe: risk difference [RD], –11.3%; 95% CI, –17.7% to –4.8%; p < 0.001 and for ANZ vs. North America: RD, –10.3%; 95% CI, –17.5% to –3.1%; p = 0.007). CONCLUSIONS: Among STARRT-AKI trial centers, significant regional practice variation exists regarding FB, timing of initiation of RRT, and initial use of continuous RRT. After adjustment, such practice variation was associated with lower ICU and hospital stay and 90-day mortality among ANZ patients compared with other regions.
SNOT‐22 subdomain outcomes following treatment for sinonasal malignancy: A prospective, multicenter study
Grimm, David R. , Beswick, Daniel M. , Maoz, Sabrina L. , Chan, Erik, Adappa, Nithin D. , Getz, Anne E., Humphreys, Ian M. , Chang, Eugene H. , Jafari, Aria , Kingdom, Todd T. , Kohanski, Michael A. , Lee, Jivianne K., Adappa, Nithin D. , Patel, Zara M. , Sim, Myung‐Shin , Smith, Timothy L. , Storm, Phillip B. , Wang, Marilene B. , Hwang, Peter H. , Wang, Eric W , Choby, Garret , Kuan, Edward C , Humphreys, Ian M , Jafari, Aria , Nayak, Jayakar V , Patel, Zara , Smith, Timothy L , Snyderman, Carl H , Hwang, Peter H , Beswick, Daniel , Grimm, David R , Maoz, Sabrina L , Choby, Garret , Adappa, Nithin D. , Geltzeiler, Mathew , Le, Christopher H. , Abuzeid, Waleed M. , Nayak, Jayakar V. , Pinheiro‐Neto, Carlos , Resnick, Adam , John, Maie A. St. , Suh, Jeffrey D.

Mayo Clinic

International Forum of Allergy & Rhinology | February 19, 2024 | Volume: 14 | Issue: 8 | Pages: 1314-1326

10.1002/alr.23338 | PMID 38372441 Get It

AbstractBackgroundPatients with sinonasal malignancy (SNM) present with significant sinonasal quality of life (QOL) impairment. Global sinonasal QOL as measured by the 22‐item Sinonasal Outcomes Test (SNOT‐22) has been shown to improve with treatment. This study aims to characterize SNOT‐22 subdomain outcomes in SNM.MethodsPatients diagnosed with SNM were prospectively enrolled in a multi‐center patient registry. SNOT‐22 scores were collected at the time of diagnosis and through the post‐treatment period for up to 5 years. Multivariable regression analysis was used to identify drivers of variation in SNOT‐22 subdomains.ResultsNote that 234 patients were reviewed, with a mean follow‐up of 22 months (3 months–64 months). Rhinologic, psychological, and sleep subdomains significantly improved versus baseline (all p < 0.05). Subanalysis of 40 patients with follow‐up at all timepoints showed statistically significant improvement in rhinologic, extra‐nasal, psychological, and sleep subdomains, with minimal clinically important difference met between 2 and 5 years in sleep and psychological subdomains. Adjuvant chemoradiation was associated with worse outcomes in rhinologic (adjusted odds ratio (5.22 [1.69–8.66])), extra‐nasal (2.21 [0.22–4.17]) and ear/facial (5.53 [2.10–8.91]) subdomains. Pterygopalatine fossa involvement was associated with worse outcomes in rhinologic (3.22 [0.54–5.93]) and ear/facial (2.97 [0.32–5.65]) subdomains. Positive margins (5.74 [2.17–9.29]) and surgical approach—combined versus endoscopic (3.41 [0.78–6.05])—were associated with worse psychological outcomes. Adjuvant radiation (2.28 [0.18–4.40]) was associated with worse sleep outcomes.ConclusionsSinonasal QOL improvements associated with treatment of SNM are driven by rhinologic, extra‐nasal, psychological, and sleep subdomains.
A script‐enabled interactive checklist document for efficient management of electronic devices in a busy multimodality radiotherapy clinic
Pepin, M. , Brost, Eric E., Klein, Kristi A., Garces, Yolanda I. , Brinkmann, Debra H. , Pepin, Mark D , Brost, Eric

Mayo Clinic

Journal of Applied Clinical Medical Physics | February 18, 2024 | Volume: 25 | Issue: 3 | Pages: No page available

10.1002/acm2.14302 | PMID 38368613 Get It

PurposeDevelop an efficient, interactive, and instructive checklist document for the management of implanted electronic medical devices in a multimodality radiotherapy clinic.MethodsThe built‐in scripting and interactivity of a popular commercial word processor was used to develop an interactive document that changes the information presented to the user based on drop‐down selections. The interactivity and scripting were compatible with the radiation oncology information system (ROIS) which allows the document to be accessible by all team members and serve as a permanent record in a patient's electronic chart.ResultsThe final interactive document, which was clinically deployed after beta testing with a group consisting of nurses and medical physicists, presents information and action plans to the user based on multiple departmental medical device decision trees that are specific to the combination of device, treatment modality, rhythm‐pacing dependence for cardiac devices, and distance from the device to the treatment volume.ConclusionA script‐enabled interactive document was developed for a busy multimodality clinic, condensing multiple comprehensive departmental guidelines spanning multiple device types and treatment modalities into a single interactive checklist accessible within the ROIS. Given the wide accessibility of the commercial word processor, this approach could be adopted by other clinics to streamline their own respective workflows.
Clinical outcomes of hypomethylating agents plus Venetoclax as frontline treatment in patients 75 years and older with acute myeloid leukemia: Real‐world data from eight US academic centers
Abaza, Yasmin , Winer, Eric S. , Shallis, Rory M. , Matthews, Andrew , Badar, Talha , Geramita, Emily , Kota, Vamsi , Swaroop, Alok , Doukas, Peter H., Bradshaw, Danielle , Helenowski, Irene , Zhang, Hui , Im, Annie , Litzow, Mark R. , Perl, Alexander E. , Altman, Jessica K. , Zhang, Hui , Matthews, Andrew H , Badar, Talha , Kota, Vamsi , Swaroop, Alok , Bradshaw, Danielle , Im, Annie , Litzow, Mark R. , Perl, Alexander E , Mesulam, M-Marsel , Abaza, Yasmin , Murthy, Guru Subramanian Guru , Doukas, Peter, Liu, Yingzhe , Atallah, Ehab

Mayo Clinic

American Journal of Hematology | February 12, 2024 | Volume: 99 | Issue: 4 | Pages: 606-614

10.1002/ajh.27231 | PMID 38342997 Get It

AbstractVenetoclax (VEN) combined with hypomethylating agents (HMAs) is the standard of care for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) unfit for intensive chemotherapy. To date, real‐world data published on HMAs plus VEN have been either single‐center studies or using community‐based electronic databases with limited details on mutational landscape, tolerability, and treatment patterns in elderly patients. Therefore, we conducted a multicenter retrospective study to assess the real‐world experience of 204 elderly patients (≥75 years) with newly diagnosed AML treated with HMAs plus VEN from eight academic centers in the United States. Overall, 64 patients achieved complete remission (CR; 38%) and 43 CR with incomplete count recovery (CRi; 26%) for a CR/CRi rate of 64%, with a median duration of response of 14.2 months (95% CI: 9.43, 22.1). Among responders, 63 patients relapsed (59%) with median overall survival (OS) after relapse of 3.4 months (95% CI, 2.4, 6.7). Median OS for the entire population was 9.5 months (95% CI, 7.85–13.5), with OS significantly worse among patients with TP53‐mutated AML (2.5 months) and improved in patients harboring NPM1, IDH1, and IDH2 mutations (13.5, 18.3, and 21.1 months, respectively). The 30‐day and 60‐day mortality rates were 9% and 19%, respectively. In conclusion, HMAs plus VEN yielded high response rates in elderly patients with newly diagnosed AML. The median OS was inferior to that reported in the VIALE‐A trial. Outcomes are dismal after failure of HMAs plus VEN, representing an area of urgent unmet clinical need.
Core outcomes in nerve surgery: development of a core outcome set for brachial plexus and upper extremity nerve injuries
Wilson, Thomas J. , Ali, Zarina S. , Davis, Gavin A , Desai, Ketan, Garozzo, Debora, Guedes, Fernando , Jack, Megan M. , Jacques, Line , Kretschmer, Thomas , Midha, Rajiv, Puffer, Ross C. , Rasulić, Lukas , Ray, Wilson Z. , Rizk, Elias , Rodríguez-Aceves, Carlos Alberto , Shapira, Yuval, Spinner, Robert J. , Zager, Eric L. , Davis, Gavin A. , Dengler, Nora F. , Mahan, Mark A , Pondaag, Willem , Smith, Brandon W. , Socolovsky, Mariano

Mayo Clinic

Journal of Neurosurgery | February 9, 2024 | Volume: 141 | Issue: 2 | Pages: 474-483

10.3171/2023.11.jns232272 | PMID 38335525 Get It

OBJECTIVE When considering traumatic brachial plexus and upper extremity nerve injuries, iatrogenic nerve injuries, and nontraumatic nerve injuries, brachial plexus and upper extremity nerve injuries are commonly encountered in clinical practice. Despite this, data synthesis and comparison of available studies are difficult. This is at least in part due to the lack of standardization in reporting and a lack of a core outcome set (COS). Thus, there is a need for a COS for adult brachial plexus and upper extremity nerve injuries (COS-BPUE). The objective of this study was to develop a COS-BPUE using a modified Delphi approach. METHODS A 5-stage approach was used to develop the COS-BPUE: 1) consortium development, 2) literature review to identify potential outcome measures, 3) Delphi survey to develop consensus on outcomes for inclusion, 4) Delphi survey to develop definitions, and 5) consensus meeting to finalize the COS and definitions. The study followed the Core Outcome Set-STAndards for Development (COS-STAD) recommendations. RESULTS The Core Outcomes in Nerve Surgery (COINS) Consortium comprised 23 participants, all neurological surgeons, representing 13 countries. The final COS-BPUE consisted of 36 data points/outcomes covering demographic, diagnostic, patient-reported outcome, motor/sensory outcome, and complication domains. Appropriate instruments, methods of testing, and definitions were set. The consensus minimum duration of follow-up was 24 months, with the consensus optimal time points for assessment being preoperatively and 3, 6, 12, and 24 months postoperatively. CONCLUSIONS The COINS Consortium developed a consensus COS and provided definitions, methods of implementation, and time points for assessment. The COS-BPUE should serve as a minimum set of data that should be collected in all future neurosurgical studies on adult brachial plexus and upper extremity nerve injuries. Incorporation of this COS should help improve consistency in reporting, data synthesis, and comparability, and should minimize outcome reporting bias.
Leadless pacemakers at 5-year follow-up: the Micra transcatheter pacing system post-approval registry
Garweg, Christophe , Clementy, Nicolas, Al-Samadi, Faisal, Iacopino, Saverio , Roberts, Paul R. , Johansen, Jens Brock , Vinolas-Prat, X., Cha, Yong‐Mei , Grubman, Eric , Bordachar, Pierre , Fagan, Dedra H. , Piccini, Jonathan P. , El-Chami, Mikhael F , Garweg, Christophe , Johansen, Jens Brock , Cha, Yong-Mei , Stromberg, Kurt , El‐Chami, Mikhael F. , Clémenty, Nicolas , Martínez‐Sande, José Luis , Tondo, Claudio , Stromberg, Kurt

Mayo Clinic

European Heart Journal | February 9, 2024 | Volume: 45 | Issue: 14 | Pages: 1241-1251

10.1093/eurheartj/ehae101 | PMID 38426911 Get It

Abstract Background and Aims Prior reports have demonstrated a favourable safety and efficacy profile of the Micra leadless pacemaker over mid-term follow-up; however, long-term outcomes in real-world clinical practice remain unknown. Updated performance of the Micra VR leadless pacemaker through five years from the worldwide post-approval registry (PAR) was assessed. Methods All Micra PAR patients undergoing implant attempts were included. Endpoints included system- or procedure-related major complications and system revision rate for any cause through 60 months post-implant. Rates were compared through 36 months post-implant to a reference dataset of 2667 transvenous pacemaker patients using Fine–Gray competing risk models. Results 1809 patients were enrolled between July 2015 and March 2018 and underwent implant attempts from 179 centres in 23 countries with a median follow-up period of 51.1 months (IQR: 21.6–64.2). The major complication rate at 60 months was 4.5% [95% confidence interval (CI): 3.6%–5.5%] and was 4.1% at 36 months, which was significantly lower than the 8.5% rate observed for transvenous systems (HR: .47, 95% CI: .36–.61; P &lt; .001). The all-cause system revision rate at 60 months was 4.9% (95% CI: 3.9%–6.1%). System revisions among Micra patients were mostly for device upgrades (41.2%) or elevated thresholds (30.6%). There were no Micra removals due to infection noted over the duration of follow-up. At 36 months, the system revision rate was significantly lower with Micra vs. transvenous systems (3.2% vs. 6.6%, P &lt; .001). Conclusions Long-term outcomes with the Micra leadless pacemaker continue to demonstrate low rates of major complications and system revisions and an extremely low incidence of infection.